MCM
LUCD icon

Masters Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Masters Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28M Hold
4,000,000
– – 0.11% 74
2026
Q1 		$4.6M Hold
4,000,000
– – 0.15% 78
2025
Q4 		$4.36M Buy
4,000,000
+727
+0% +$813 0.18% 70
2025
Q3 		$4.04M Buy
3,999,273
+1,272,000
+47% +$1.39M 0.15% 72
2025
Q2 		$3.14M Hold
2,727,273
– – 0.12% 65
2025
Q1 		$4.06M Buy
+2,727,273
New +$3.27M 0.2% 63

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Masters Capital Management's LUCD Position: Q2 2026 in Review

Masters Capital Management held its Lucid Diagnostics (LUCD) position steady in Q2 2026 at 4,000,000 shares worth $4.28M. The position accounts for 0.11% of the portfolio, ranked #74.

Masters Capital Management first reported a position in LUCD in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.6M in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Masters Capital Management held 4,000,000 shares of Lucid Diagnostics worth $4.28M as of Q2 2026.
  • Masters Capital Management left its Lucid Diagnostics share count unchanged in Q2 2026.
  • Lucid Diagnostics made up 0.11% of Masters Capital Management's portfolio in Q2 2026, its #74 holding.
  • Masters Capital Management first reported a position in Lucid Diagnostics in Q1 2025 and has held it in 6 quarters since.
  • Masters Capital Management's Lucid Diagnostics position peaked at $4.6M in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Masters Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.